
-
Apellis Pharmaceuticals NASDAQ:APLS Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
Location: 100 Fifth Avenue, Massachusetts, 02451, United States | Website: apellis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.941B
Cash
416.1M
Avg Qtr Burn
-21.97M
Short % of Float
22.93%
Insider Ownership
13.86%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SYFOVRE™ (Intravitreal pegcetacoplan) Details Geographic atrophy, Age-related macular degeneration | Approved Quarterly sales | |
Empaveli (systemic pegcetacoplan) (APL-2) Details Paroxysmal nocturnal hemoglobinuria | Approved Quarterly sales | |
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy | PDUFA Approval decision | |
Systemic pegcetacoplan (APL-2) Details Hematopoietic stem cell transplantation thrombotic microangiopathies | Phase 2 Data readout | |
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy | Phase 2 Update | |
APL-3007 + SYFOVRE Details Autoimmune disease, Inflammatory disease | Phase 2 Initiation | |
Systemic pegcetacoplan (APL-2) Details Cold agglutinin disease | Failed Discontinued | |
Intravenous APL-9 Details ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies) | Failed Discontinued | |
Systemic pegcetacoplan (APL-2) Details Amyotrophic lateral sclerosis | Failed Discontinued |